BusinessRhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual MeetingBy Nasdaq OMXApr 10, 2018, 11:00 AM UTC
BusinesseFFECTOR Announces Appointment of John W. Smither to its Board of DirectorsBy Nasdaq OMXMar 23, 2018, 6:00 PM UTC
BusinessRhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USABy Nasdaq OMXOct 24, 2017, 11:00 AM UTC
BusinessSurefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in MexicoBy Nasdaq OMXMar 20, 2017, 10:00 AM UTC
